FFG
CCCC icon

Ford Financial Group’s C4 Therapeutics CCCC Stock Holding History

Ford Financial Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50
Closed -$1 – 178
2021
Q4 		$1 Buy
+50
New +$1.98K ﹤0.01% 445

Other funds holding CCCC

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Ford Financial Group's CCCC Position: Q1 2022 in Review

Ford Financial Group sold out of C4 Therapeutics (CCCC) in Q1 2022, closing a stake of 50 shares — an estimated $1 sold.

Ford Financial Group first reported a position in CCCC in Q4 2021 and held it in 1 quarter. The position peaked at $1 in Q4 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

  • Ford Financial Group reported no remaining C4 Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ford Financial Group sold 50 C4 Therapeutics shares in Q1 2022, an estimated $1.
  • Ford Financial Group first reported a position in C4 Therapeutics in Q4 2021 and held it in 1 quarter.
  • Ford Financial Group's C4 Therapeutics position peaked at $1 in Q4 2021.
  • 125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Ford Financial Group's 13F filing for Q1 2022, filed 13 Apr 2022.